Zinc Finger Proteins Modulate PEDF Gene Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-angiogenic therapies are often ineffective as they primarily target a single angiogenic factor, requiring repeated administration and failing to inhibit angiogenesis in many situations due to the complexity of the process regulated by multiple pro- and anti-angiogenic factors.
Innovation Solution
Engineered zinc finger proteins that modulate the expression of the PEDF gene, comprising specific amino acid sequences and functional domains, are used to regulate angiogenesis by binding to target sites in the PEDF and VEGF genes, thereby inhibiting excessive angiogenesis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current anti-angiogenic therapies target a single angiogenic factor, then the treatment mechanism is simple, but the therapeutic effectiveness is insufficient
Solution Approach 1:
The patent employs a combination therapy approach that simultaneously targets multiple angiogenic factors (VEGF, FGF, PDGF, TGF-beta, TNF-alpha, IL-1beta) using different therapeutic agents. This multi-functional strategy addresses the complexity of angiogenesis regulation by interfering with multiple pro-angiogenic pathways concurrently, thereby improving therapeutic effectiveness without requiring an overly complex treatment mechanism
Solution Approach 2:
The patent utilizes a composite therapeutic regimen combining multiple distinct anti-angiogenic agents with different mechanisms of action. This composite approach integrates various therapeutic modalities (monoclonal antibodies, small molecule inhibitors, gene therapy) to create a synergistic effect that overcomes the limitations of single-target therapies while maintaining manageable treatment complexity
2Duration of action of stationary object
If anti-angiogenic therapy requires repeated administration, then the inhibition effect can be maintained, but the treatment frequency and burden increase
Solution Approach 1:
The patent incorporates gene therapy approaches that introduce therapeutic genes (such as anti-VEGF antibodies or inhibitory RNA) directly into target cells. This preliminary genetic modification enables the cells to produce therapeutic agents continuously or over extended periods, thereby maintaining prolonged inhibition of angiogenesis and reducing the frequency of repeated administrations required with conventional therapies
Solution Approach 2:
The patent designs therapeutic systems where modified cells or implanted devices continuously produce or release anti-angiogenic factors autonomously. This self-service mechanism allows the treatment to maintain its effect without requiring frequent external intervention, thereby extending the duration of action and reducing treatment burden while maintaining therapeutic efficacy
3Reliability
If a single angiogenic factor is targeted, then the therapy is specific, but it fails to prevent angiogenesis in many situations due to process complexity
Solution Approach 1:
The patent employs a combination therapy approach that simultaneously targets multiple angiogenic factors (VEGF, FGF, PDGF, TGF-beta, TNF-alpha, IL-1beta) using different therapeutic agents. This multi-functional strategy addresses the complexity of angiogenesis regulation by interfering with multiple pro-angiogenic pathways concurrently, thereby improving therapeutic effectiveness without requiring an overly complex treatment mechanism
Solution Approach 2:
The patent adjusts therapeutic parameters by selecting different combinations of anti-angiogenic agents and dosing regimens tailored to specific disease conditions and patient needs. This parameter optimization enables the therapy to adapt to various clinical scenarios (cancer, AMD, diabetic retinopathy, etc.) while maintaining high inhibition efficacy across different applications
Data Source
AI summary
Disclosed herein are methods and compositions for treatment of conditions requiring inhibition of angiogenesis. Such conditions include those characterized by neovascularization, such as retinopathies, macular degeneration and various malignancies.